Breast Cancer Monoclonal Antibodies Market 2024-2033: Competitor Assessment, Industry Size And Major Players

The breast cancer monoclonal antibodies market size has grown strongly in recent years. It will grow from $18.97 billion in 2023 to $20.18 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to rising prevalence of breast cancer, increasing awareness of breast cancer monoclonal antibodies, growing clinical efficacy, patient demand.

The breast cancer monoclonal antibodies market size is expected to see strongly grown in the next few years. It will grow to $27.8 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to emerging targets, biosimilars, combination therapies, global incidence and aging population, personalized medicine. Major trends in the forecast period include advances in early breast cancer detection, immunotherapy integration, liquid biopsies, companion diagnostics, adjuvant and neoadjuvant therapies, long-term survivorship support.

Market Overview -
Breast cancer monoclonal antibodies (mAbs) refer to the use of antibodies in the treatment of both early-stage and advanced breast cancer. It functions by identifying and locating particular proteins on cancer cells. Every MAB recognises a different protein. Therefore, different MABs must be created to target various cancer types. They kill the cancer cell in various ways depending on the protein they are targeting.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=3450&type=smp

Rising Breast Cancer Incidence Fuels Growth In The Market
Rising breast cancer incidences are expected to drive the breast cancer monoclonal antibody market's growth. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of breast cancer cases increased from 284,200 in 2021 to 300,590 in 2023, reflecting a growth of 5.76%. Thus, the rising prevalence of breast cancer globally is expected to boost the growth of the breast cancer monoclonal antibody market.

Competitive Landscape -
Major companies operating in the breast cancer monoclonal antibodies market include Amgen Inc., Mylan N.V., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc., Daiichi Sankyo Company Ltd., Biocad, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Array BioPharma Inc., Celldex Therapeutics Inc., Celltrion Inc., F. Hoffmann-La Roche AG, Immunomedics Inc., MacroGenics Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Puma Biotechnology Inc., Seattle Genetics Inc., AstraZeneca plc, Eddingpharm, Eisai Co. Ltd., Galena Biopharma Inc., ImmunoGen Inc., Eli Lilly and Company, AbbVie Inc., Johnson & Johnson, Mersana Therapeutics Inc., Immunocore Limited, Immunovative Therapies Ltd.

Innovative Combination Therapies Redefining The Breast Cancer Treatment
Companies in the breast cancer monoclonal antibodies market are investing in targeted and combination therapy, which has proven to be more effective and less toxic than the traditional treatment options. Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease. For instance, in May 2022, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, introduced PHESGO, a groundbreaking treatment for breast cancer. PHESGO represents the first-ever fixed-dose formulation in oncology, combining two monoclonal antibodies, Perjeta (pertuzumab) and Herceptin (trastuzumab), with hyaluronidase. It is administered via subcutaneous injection in conjunction with intravenous (IV) chemotherapy for the management of both early and metastatic breast cancer.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/breast-cancer-monoclonal-antibodie-global-market-report

Key Segments -
The breast cancer monoclonal antibodies market covered in this report is segmented -
1) By Product: Naked Mabs, Conjugated Mabs
2) By Treatment: Chemotherapy, Surgery & Radiation Therapy, Targeted Therapy, Biologic Therapy, Hormone Therapy
3) By End-User: Hospitals, Retail Pharmacies

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.